11-Mar-2020 | Facts and Factors
Findings from Facts and Factors report “Enzyme Replacement Therapy Market By Enzyme (Imiglucerase, Agalsidase Beta, Taliglucerase, Velaglucerase Alfa, Laronidase, Alglucosidase Alfa and Others), therapeutic condition (Pompe’s disease, Gaucher’s disease, MPS, Fabry’s disease, SCID, and others), Route of administration (oral and parenteral) and End-user (hospitals, infusion centers, and others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global Enzyme Replacement Therapy market in 2019 was approximately USD 6,826.45 million. The market is expected to grow at a CAGR of 5.86% and is anticipated to reach around USD 10,150.88 million by 2026.
Enzymes are the proteins that conduct catalytic roles in various biochemical reactions inside the body. Lysosomal Storage Disease (LSD) is triggered by a deficit in the body's enzymes and leads to tissue inflammation. Enzyme replacement therapy for enzyme-deficient patients is the process of replacement of enzymes with artificial enzymes. The treatment is done by intravenous infusion or oral delivery of the preparation-containing enzyme. Enzyme substitution treatments are intended to increase enzyme production, but not to change the origin of the underlined disorder. Enzyme replacement therapy for disorders such as Fabry disease, Hunter syndrome, digestive diseases, and Gaucher disease, is currently available.
Browse the full “Enzyme Replacement Therapy Market By Enzyme (Imiglucerase, Agalsidase Beta, Taliglucerase, Velaglucerase Alfa, Laronidase, Alglucosidase Alfa and Others), therapeutic condition (Pompe’s disease, Gaucher’s disease, MPS, Fabry’s disease, SCID, and others), Route of administration (oral and parenteral) and End-user (hospitals, infusion centers, and others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" report at https://www.fnfresearch.com/enzyme-replacement-therapy-market-by-enzyme-imiglucerase-agalsidase-692
Because of factors such as broader therapy supply, ease of enzyme replacement therapy acceptance guidance, and benefits such as fewer side effects, the global enzyme replacement therapy market is likely to experience high growth over the projected timeframe. Factors such as easy access to the enzyme replacement therapy and government funding for services are already expected to drive market growth. However, insurance issues in different countries and fewer therapy side effects can have a significant impact on the success of enzyme replacement therapy.
The market for Enzyme Replacement Therapy is divided into the enzyme, therapeutic condition, route of administration, end-user, and region. The enzymes segment is classified into Agalsidase Beta, Imiglucerase, Taliglucerase, Laronidase, Velaglucerase Alfa, Alglucosidase Alfa, and other enzymes. One of the important factors for the big market share of enzymes such as velaglucerasealfaand imiglucerase, is the largest occurrence of Gaucher disease. Better use of pancreatic enzymes such as amylase, lipase, and protease is typically seen in cancer patients to treat exocrine pancreatic insufficiency (EPI). The therapeutic condition segment is bifurcated into Gaucher’s disease, Pompe’s disease, SCID, MPS, Fabry’s disease, and others. Because of its large market impact, Gaucher's disease has a high incidence. Gaucher disease is a disorder that is acquired through recessive mutation. The route of administration is bifurcated into oral and parenteral. The end-user segment is segmented into hospitals, infusion centers, and others.
Geography-wise the market is segmented into the regions that comprise the current and forecast market demand for the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa with its further fragmentation into major countries. North America also dominated the market in 2019. Well-developed health-care systems and the emergence of North America's leading market players have spurred regional segment growth. Additionally, the introduction of advanced technologies and increased focus on drug development in this area is expected to drive industry growth.
Some of the players included in Enzyme Replacement Therapy are AbbVie, Actelion, Alexion, Allergan, BioMarin, Digestive Care, Horizon Pharma, Johnson & Johnson, Leadiant Biosciences, Pfizer, Recordati Rare Diseases, Sanofi and Shire amongst others.
This report segments the Enzyme Replacement Therapy Market as follows:
Global Enzyme Replacement Therapy Market: Enzyme Segment Analysis
- Agalsidase Beta
- Velaglucerase Alfa
- Alglucosidase Alfa
Global Enzyme Replacement Therapy Market: Therapeutic Condition Segment Analysis
- Gaucher Disease
- Fabry Disease
- Pompe Disease
Global Enzyme Replacement Therapy Market: Route of Administration Segment Analysis
Global Enzyme Replacement Therapy Market: End-user Segment Analysis
- Infusion Centers
Global Enzyme Replacement Therapy: Regional Segment Analysis
- North America
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Facts & Factors
Level 8, International Finance Center, Tower 2,
8 Century Avenue, Shanghai,
Postal - 200120, China
Tel: +86 21 80360450
Email: [email protected]